 |
Case Report
Acute renal infarction associated with Semaglutide (Ozempec) use
1 MB BCh, Am B Med, Am B Nephrology, FRCP (Ed), Department of Medicine, Faculty of Medicine, Kuwait University, 13110 Safat, Kuwait
2 MB BCh, Department of ENT and ICU, Farwania Hospital, Ministry of Health, Kuwait
3 MD, EDR, IMAGES Diagnostic Center, Kuwait
Address correspondence to:
Kamel El-Reshaid
Professor, Department of Medicine, Faculty of Medicine, Kuwait University, P O Box 24923, 13110 Safat,
Kuwait
Message to Corresponding Author
Article ID: 101491Z01KE2025
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
El-Reshaid K, Al-Bader A, Abou-deeb S. Acute renal infarction associated with Semaglutide (Ozempec) use. Int J Case Rep Images 2025;16(1):16–19.ABSTRACT
Introduction: Semaglutide (S) is a glucagon-like peptide-1 receptor agonist that is approved by Food and Drug Administration for treatment of type 2 diabetes and obesity. Moreover, it reduced the risk of renal failure, cardiovascular death rates, nonfatal myocardial infarction, and nonfatal stroke. Initially, adverse effects (AE) were mainly gastrointestinal. However, there is growing concern about rarer and more serious AE, such as higher risk of pancreatitis, bowel obstruction, gastroparesis, and venous thrombosis. Arterial disease, leading to renal infarction, has not been reported following its use.
Case Report: A 51-years-old man presented with sudden left loin pain for two days. Computed tomography with contrast showed wedge-shaped avascular anterior aspect of left kidney. Arteriogram showed abrupt loss of flow in a corresponding 1 of the 2 feeding arteries to left kidney without focal abnormalities in its proximal portion, second left renal artery, right one, aorta, and its branches. The patient did not have family history or laboratory evidence of hypercoagulable disorder. Echocardiogram did not show mural and valvular disease. 24-hour Holter-monitoring did not show arrhythmia. S was the only medication he had received in the previous six weeks for moderate obesity. The drug was discontinued, and the patient was treated with heparin for three days then Rivaroxaban 20 mg daily for six months. On follow-up, he did not have subsequent thrombotic events up to 1 year of follow-up.
Conclusion: In selected population, S can induce arterial thrombosis-in-situ.
Keywords: Complication, Infarction, Kidney, Semaglutide
SUPPORTING INFORMATION
Author Contributions
Kamel El-Reshaid - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Abdulmohsen Al-Bader - Acquisition of data, Analysis of data, Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Samer Abou-deeb - Acquisition of data, Analysis of data, Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guaranter of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2025 Kamel El-Reshaid et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
